Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of LENVIMA® (lenvatinib) in Differentiated Thyroid Cancer at ESMO Asia 2020

Results from the study showed: In the primary efficacy analysis, ORR WK24 was 57.3% (95% CI: 46.1–68.5) in the 24 mg arm vs. 40.3% (95% CI: 29.3–51.2) in the 18 mg arm (odds ratio: 0.50 [95% CI: 0.26–0.96]). The 18 mg dose did not show noninferiority in efficacy to the 24 mg dose as measured by ORR WK24.

Posted: 2020-11-21 00:30:00

Read Full Article

< Prev		Next >

Donate now!

Donate now, contribute to EGR & NEXUS-IBA projects

Free consultation

If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.

We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.

EGR local time

Verse of the day

A prophet is not without honour, save in his own country and in his own house. Matthew, 13. 57

Main Menu

Polls

Is wealth an indication of God’s favor or blessing?

	Yes
	No
	Somehow
	I do not know

EGR European Gospel Radio